Search

Displaying results 2111 - 2120 of 4691 in total
  1. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  2. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by … [A181523] This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4,

  3. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about.

  4. Drug

    Gimeracil

    go.drugbank.com/drugs/DB09257
    ApprovedInvestigational

    It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408]. … Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

  5. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  6. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been disc...

  7. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].

  8. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  9. Drug

    Diethylcarbamazine

    go.drugbank.com/drugs/DB00711
    ApprovedInvestigationalVet approvedWithdrawn

    An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.

  10. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … [L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.